| ■ 영문 제목 : mRNA Synthesis Raw Materials Market Size, Share & Trends Analysis Report By Type (Capping Agents, Nucleotides, Plasmid DNA), By Application, By End-user, By Region, And Segment Forecasts, 2023 - 2030
|
 | ■ 상품코드 : GRV23MA023
■ 조사/발행회사 : Grand View Research
■ 발행일 : 2023년 1월
■ 페이지수 : 150
■ 작성언어 : 영어
■ 보고서 형태 : PDF
■ 납품 방식 : E메일 (납기:3일)
■ 조사대상 지역 : 세계
■ 산업 분야 : 바이오
|
■ 판매가격 / 옵션
(부가세 10% 별도)
| Single User (1인 열람용) | USD5,950 ⇒환산￦8,032,500 | 견적의뢰/주문/질문 |
| Multi User (5인 열람용) | USD6,950 ⇒환산￦9,382,500 | 견적의뢰/주문/질문 |
| Global/corporate License (기업 열람용) | USD8,950 ⇒환산￦12,082,500 | 견적의뢰/구입/질문 |
※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.
|
미국 Grand View Research (그랜드뷰리서치)는 세계의 mRNA 합성 재료 시장 규모가 2023년부터 2030년 사이에 연평균 2.1% 성장하여, 2030년에는 33억 달러에 달할 것으로 전망하고 있습니다. 본 조사 보고서는 세계의 mRNA 합성 재료 시장을 조사대상으로 하여, 조사 방법 및 범위, 개요, 시장 변동/동향/범위, 종류별 (캡핑제, 뉴클레오티드, 플라스미드 DNA, 기타) 분석, 용도별 (치료제 생산, 백신 생산, 기타) 분석, 최종 용도별 (바이오 의약품 및 제약 기업, CRO 및 CMO, 학술 및 연구 기관) 분석, 지역별 (북미, 유럽, 아시아 태평양, 중남미, 중동/아프리카) 분석, 경쟁 현황 등의 내용을 게재하고 있습니다. 또한 본 자료는 F. Hoffmann - La Roche Ltd., Jena Bioscience Gmbh, Merck KGaA, Yeasen Biotechnology (Shanghai) Co., Ltd., BOC Sciences, Thermo Fisher Scientific, Inc., Maravai Lifesciences, New England Biolabs, Creative Biogene, Hongene 등의 기업 정보가 포함되어 있습니다.
・조사 방법 및 범위
・개요
・시장 변동/동향/범위
・세계의 mRNA 합성 재료 시장 규모 : 종류별
- 캡핑제의 시장 규모
- 뉴클레오티드의 시장 규모
- 플라스미드 DNA의 시장 규모
- 기타 종류의 시장 규모
・세계의 mRNA 합성 재료 시장 규모 : 용도별
- 치료제 생산에 사용되는 mRNA 합성 재료의 시장 규모
- 백신 생산에 사용되는 mRNA 합성 재료의 시장 규모
- 기타 용도에 사용되는 mRNA 합성 재료의 시장 규모
・세계의 mRNA 합성 재료 시장 규모 : 최종 용도별
- 바이오 의약품 및 제약 기업에서 사용되는 mRNA 합성 재료의 시장 규모
- CRO 및 CMO에서 사용되는 mRNA 합성 재료의 시장 규모
- 학술 및 연구 기관에서 사용되는 mRNA 합성 재료의 시장 규모
・세계의 mRNA 합성 재료 시장 규모 : 지역별
- 북미의 mRNA 합성 재료 시장 규모
- 유럽의 mRNA 합성 재료 시장 규모
- 아시아 태평양의 mRNA 합성 재료 시장 규모
- 중남미의 mRNA 합성 재료 시장 규모
- 중동/아프리카의 mRNA 합성 재료 시장 규모
・경쟁 현황
・기업 정보 |
■ 보고서 개요mRNA Synthesis Raw Materials Market Growth & Trends
The global mRNA synthesis raw materials market size is projected to reach USD 3.3 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 2.1% from 2023 to 2030. The major factors driving the market growth include growing academic and industrial interest in mRNA technology, the advantages of mRNA vaccines, and increasing funding for research. In addition, the increasing therapeutic applications of RNA technology are projected to offer lucrative opportunities for the mRNA synthesis raw materials market during the forecast period.
The COVID-19 pandemic has increased the demand for mRNA synthesis raw materials for developing an efficient vaccine to battle infectious diseases. mRNA vaccines are a safe and efficient method for preventing COVID-19. In addition, the advantages associated with the mRNA COVID-19 vaccines have sparked the attention of pharmaceutical businesses in delivering vaccines swiftly across the globe. For instance, the National Institute of Allergy and Infectious Diseases and Moderna, Inc. mutually developed the mRNA-1273 (NIAID) in March 2020. As a result, the usage of mRNA vaccines increased significantly during the COVID-19 pandemic.
Furthermore, many major pharmaceutical firms have started working on mRNA-based therapeutics, including Novartis, Alexion, AstraZeneca, Pfizer, Sanofi Pasteur, and Shire. For instance, in January 2022, according to a development and option agreement between Pfizer Inc. and Acuitas Therapeutics, Pfizer will have the option to license Acuitas’ LNP technology for up to 10 targets for the development of mRNA therapeutics & vaccines. Therefore, the adoption rate of mRNA synthesis raw materials has increased among pharma & biotech companies, which further fuels the market growth.
Moreover, due to the temporary nature of mRNA translation and lack of integration of the foreign material into the cell’s genome, the resulting cellular therapeutic product has a number of benefits over the one obtained by a more conventional approach. Some of the advantages include easier production under acceptable manufacturing procedures, reduced cytotoxicity from on-target off-tumor effects, and better clinical validation and regulatory treatment. Thus, such advantages are expected to increase the demand for mRNA therapeutics and further boost market growth.
Additionally, regarding the treatment and prevention of several diseases, mRNA-based technologies have been proven to be incredibly promising. Tremendous advances in technology and scientific study over the past ten years have made mRNA a feasible therapeutic option, eliminating some of the problems with its use, such as its brief half-life and innate immunogenicity. For instance, as mRNA technology advances, its fusion with new adoptive immunotherapies may result in safer and more efficient methods, such as the creation of cutting-edge chimeric antigen receptor T-cells. Therefore, advancements in mRNA technology are projected to open new avenues for market growth.
However, the high cost of raw materials may impede the market during the study period. For instance, the purchase price of raw materials, such as CleanCap AG, accounts for around 45% of the total raw material costs incurred while producing both vaccines. In addition, the regulatory framework pertaining to approval processes has always been the most critical restraining factor in the biotechnology, pharmaceutical, and medical technology industry. The absence of effective regulatory framework/guidelines for the therapeutic sector in developing countries such as China and India, where the mRNA synthesis raw materials market holds great growth potential due to the presence of a large patient base, is anticipated to impede the market growth in the coming years.
mRNA Synthesis Raw Materials Market Report Highlights
• The capping agents segment held the largest share of 40.6% in 2022 owing to the advancements in the capping technology and their applications in the biopharma industry and research
• By application, the vaccine production segment captured the highest share of 85.30% in 2022. This can be attributed to the rapid production of mRNA vaccines compared to the conventional vaccines that use cell-culture-based production routes, which are often prone to failure
• North America held the highest revenue share of 35.5% in 2022, due to the presence of key players, the availability of an established commercial infrastructure for biotechnology and pharmaceutical companies, and high research and development investments in the region
• By end-user, the biopharmaceutical and pharmaceutical companies segment dominated the market in 2022 due to the increasing investments in the biopharmaceutical sector and the rising pipeline, which has boosted the need for mRNA synthesis raw materials
■ 보고서 목차Table of Contents
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates And Forecast Timeline
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Market Variables, Trends, & Scope
3.1 Parent Market Analysis
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Growing Academic And Industrial Interest In mRNA Technology
3.2.1.2 Advantages Of mRNA Vaccines
3.2.1.3 Increasing Funding For mRNA Research
3.2.2 Market Restraint Analysis
3.2.2.1 Nonexistence Of Effective Government Regulations For mRNA – Based Product Approvals
3.2.2.2 High Cost Of mRNA Synthesis Raw Materials
3.2.3 Market Challange Analysis
3.2.3.1 Lack Of Long – Lasting And Affordable Manufacturing Processes
3.3 Penetration &Growth Prospect Mapping
3.4 mRNA Synthesis Raw Materials Market – Porter’s Analysis
3.5 mRNA Synthesis Raw Materials Market – Swot Analysis
3.6 Covid – 19 Impact Analysis
Chapter 4 Type Business Analysis
4.1 mRNA Synthesis Raw Materials Market – Type Movement Analysis
4.2 Capping Agents
4.2.1 Global Capping Agents Market, 2018 – 2030 (USD Million)
4.3 Nucleotides
4.3.1 Global Nucleotides Market, 2018 – 2030 (USD Million)
4.4 Plasmid Dna
4.4.1 Global Plasmid Dna Market, 2018 – 2030 (USD Million)
4.5 Others
4.5.1 Global Other Types Market, 2018 – 2030 (USD Million)
Chapter 5 Application Business Analysis
5.1 mRNA Synthesis Raw Materials Market – Application Movement Analysis
5.2 Therapeutics Production
5.2.1 Global Therapeutics Production Market, 2018 – 2030 (USD Million)
5.3 Vaccine Production
5.3.1 Global Vaccine Production Market, 2018 – 2030 (USD Million)
5.4 Others
5.4.1 Global Other Applications Market, 2018 – 2030 (USD Million)
Chapter 6 End – User Business Analysis
6.1 mRNA Synthesis Raw Materials Market – End User Movement Analysis
6.2 Biopharmaceutical & Pharmaceutical Companies
6.2.1 Global Biopharmaceutical & Pharmaceutical Companies, 2018 – 2030 (USD Million)
6.3 Cros & Cmos
6.3.1 Global Cros & Cmos, 2018 – 2030 (USD Million)
6.4 Academic And Research Institutions
6.4.1 Global Academic And Research Institutions, 2018 – 2030 (USD Million)
Chapter 7 Regional Business Analysis
7.1 mRNA Synthesis Raw Materials Market: Regional Movement Analysis
7.2 North America
7.2.1 Swot Analysis
7.2.1.1 North America mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 Key Country Dynamics
7.2.2.2 Competitive Scenario
7.2.2.3 Regulatory Framework
7.2.2.4 U.S. mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.2.3 Canada
7.2.3.1 Key country dynamics
7.2.3.2 Competitive scenario
7.2.3.3 Regulatory framework
7.2.3.4 Canada mRNA synthesis raw materials market, 2018 – 2030 (USD Million)
7.3 Europe
7.3.1 Swot Analysis
7.3.1.1 Europe mRNA Synthesis Raw Materials Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.3.2 Germany
7.3.2.1 Key Country Dynamics
7.3.2.2 Competitive Scenario
7.3.2.3 Regulatory Framework
7.3.2.4 Germany mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.3.3 U.K.
7.3.3.1 Key Country Dynamics
7.3.3.2 Competitive Scenario
7.3.3.3 Regulatory Framework
7.3.3.4 Uk mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.3.4 France
7.3.4.1 Key Country Dynamics
7.3.4.2 Competitive Scenario
7.3.4.3 Regulatory Framework
7.3.4.4 France mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.3.5 Italy
7.3.5.1 Key Country Dynamics
7.3.5.2 Competitive Scenario
7.3.5.3 Regulatory Framework
7.3.5.5 Italy mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.3.6 Spain
7.3.6.1 Key Country Dynamics
7.3.6.2 Competitive Scenario
7.3.6.3 Regulatory Framework
7.3.6.4 Spain mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.3.7 Denmark
7.3.7.1 Key Country Dynamics
7.3.7.2 Competitive Scenario
7.3.7.3 Regulatory Framework
7.3.7.4 Denmark mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.3.8 Sweden
7.3.8.1 Key Country Dynamics
7.3.8.2 Competitive Scenario
7.3.8.3 Regulatory Framework
7.3.8.4 Sweden mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.3.9 Norway
7.3.9.1 Key country dynamics
7.3.9.2 Competitive scenario
7.3.9.3 Regulatory framework
7.3.9.4 Norway mRNA synthesis raw materials market, 2018 – 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Swot Analysis
7.4.1.1 Asia Pacific mRNA Synthesis Raw Materials, 2018 – 2030 (USD Million)
7.4.2 Japan
7.4.2.1 Key Country Dynamics
7.4.2.2 Competitive Scenario
7.4.2.3 Regulatory Framework
7.4.2.4 Japan mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.4.3 China
7.4.3.1 Key Country Dynamics
7.4.3.2 Competitive Scenario
7.4.3.3 Regulatory Framework
7.4.3.4 China mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.4.4 India
7.4.4.1 Key Country Dynamics
7.4.4.2 Competitive Scenario
7.4.4.3 Regulatory Framework
7.4.4.4 India mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.4.5 Australia
7.4.5.1 Key Country Dynamics
7.4.5.2 Competitive Scenario
7.4.5.3 Regulatory Framework
7.4.5.4 Australia mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.4.6 South Korea
7.4.6.1 Key Country Dynamics
7.4.6.2 Competitive Scenario
7.4.6.3 Regulatory Framework
7.4.6.4 South Korea mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.4.7 Thailand
7.4.7.1 Key country dynamics
7.4.7.2 Competitive scenario
7.4.7.3 Regulatory framework
7.4.7.4 Thailand mRNA synthesis raw materials market, 2018 – 2030 (USD Million)
7.5 Latin America
7.5.1 Swot Analysis
7.5.1.1 Latin America mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Key Country Dynamics
7.5.2.2 Competitive Scenario
7.5.2.3 Regulatory Framework
7.5.2.4 Brazil mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.5.3 Mexico
7.5.3.1 Key Country Dynamics
7.5.3.2 Competitive Scenario
7.5.3.3 Regulatory Framework
7.5.3.4 Mexico mRNA Synthesis Raw Materials Market, 2018 – 2030 (USD Million)
7.5.4 Argentina
7.5.4.1 Key country dynamics
7.5.4.2 Competitive scenario
7.5.4.3 Regulatory framework
7.5.4.4 Argentina mRNA synthesis raw materials market, 2018 – 2030 (USD Million)
7.6 Middle East & Africa
7.6.1 Swot Analysis
7.6.1.1 Mea mRNA Synthesis Raw Materials Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 Key country dynamics
7.6.2.2 Competitive scenario
7.6.2.3 Regulatory framework
7.6.2.4 South Africa mRNA synthesis raw materials market estimates and forecast, 2018 – 2030 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Key country dynamics
7.6.3.2 Competitive scenario
7.6.3.3 Regulatory framework
7.6.3.4 Saudi Arabia mRNA synthesis raw materials market estimates and forecast, 2018 – 2030 (USD Million)
7.6.4 UAE
7.6.4.1 Key country dynamics
7.6.4.2 Competitive scenario
7.6.4.3 Regulatory framework
7.6.4.4 UAE mRNA synthesis raw materials market estimates and forecast, 2018 – 2030 (USD Million)
7.6.5 KUWAIT
7.6.5.1 Key country dynamics
7.6.5.2 Competitive scenario
7.6.5.3 Regulatory framework
7.6.5.4 Kuwait mRNA synthesis raw materials market estimates and forecast, 2018 – 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Participant’s Overview
8.1.1 F. Hoffmann – La Roche Ltd.
8.1.2 Jena Bioscience Gmbh
8.1.3 Merck KGaA
8.1.4 Yeasen Biotechnology (Shanghai) Co.,Ltd.
8.1.5 BOC Sciences
8.1.6 Thermo Fisher Scientific, Inc.
8.1.7 Maravai Lifesciences
8.1.8 New England Biolabs
8.1.9 Creative Biogene
8.1.10 Hongene
8.2 Financial Performance
8.3 Participant Categorization
8.3.1 Market Leaders
8.3.1.1 mRNA Synthesis Raw Materials Market Share Analysis, 2022
8.3.2 Strategy Mapping
8.3.2.1 Expansion
8.3.2.2 Acquisition
8.3.2.3 Collaborations
8.3.2.4 Product/service launch
8.3.2.5 Partnerships
8.3.2.6 Others
|
| ※본 조사보고서 [세계의 mRNA 합성 재료 시장 (2023~2030) : 캡핑제, 뉴클레오티드, 플라스미드 DNA] (코드 : GRV23MA023) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 mRNA 합성 재료 시장 (2023~2030) : 캡핑제, 뉴클레오티드, 플라스미드 DNA] 에 대해서 E메일 문의는 여기를 클릭하세요. |
※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!
